DOCSLIB.ORG

Pollutants in Urban Waste Water and Sewage Sludge

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pollutants in Urban Waste Water and Sewage Sludge Section 6. Case Studies 6 CASE STUDIES (a) Platinum Group Metals in Urban Environment (b) Sustainable Urban Drainage (c) Artisanal activities in Vicenza, Northern Italy (d) Pharmaceuticals in the Urban Environment (e) Personal Care Products, Fragrances in Urban Waste Water and Sewage Sludge (f) Surfactants in Urban Wastewaters and Sewage Sludge (g) Use of Polyelectrolytes; The Acrylamide Monomer in Water Treatment (h) Landfill leachate (i) Potentially Toxic Elements (PTE) transfers to Sewage Sludge (j) Effect of Chemical Phosphate Removal on PTE Content in Sludge 113 Section 6. Case Studies (a) Platinum Group Metals in the Urban Environment Introduction The platinum group of metals (PGMs), sometimes referred to as the platinum group elements (PGEs), comprise the rare metals platinum (Pt), palladium (Pd), rhodium (Rh), ruthenium (Ru), iridium (Ir) and osmium (Os) and are naturally present in a few parts per billion (mg/kg) in the earth’s crust. The elements are noble chemically unreactive metals, and are found in nature as native alloys, consisting mainly of platinum. Recently these metals have gained importance as industrial catalysts including vehicle exhaust catalysts (VECs). This use and possible implications for human health were the subject of an earlier review undertaken by Imperial College, London for the UK Department of the Environment (Farago et al, 1995; 1996). Increasing understanding of the environmental damage of vehicle emissions has led to the introduction of stringent emission control standards throughout the western world. Since 1974 all new cars imported or produced in the United States have had catalytic convertors fitted, cutting down hydrocarbon and carbon monoxide emissions. In 1977 they were fitted to a substantial proportion of all cars sold in America, where at the time, this application accounted for 32% of the total Pt usage (Herbert, et al., 1980). Vehicle exhaust catalysts have also been used in Japan since 1974. Vehicle exhaust catalysts were also introduced in Germany in 1985, in Australia in 1986, and into the UK at the beginning of 1993 in response to the emission standards equivalent to the US standards which were introduced in the EC at that time. Other uses of PGMs are noted in later sections. Sources The PGMs are found in nickel, copper and iron sulphide seams (Bradford, 1988). They are currently mined in South Africa, Siberia and Sudbury, Ontario. World mine production of the PGMs, of which 40-50% is platinum, has steadily increased since 1970. This reflects the increasing world-wide use of PGM vehicle catalysts (IPCS, 1991). From 1988-1992 world mine production was essentially constant at around 255 tonnes per year (WMS, 1994). The amount of PGMs present in the earth’s crust down to a depth of 5km, and hence technologically attainable, are still enormous when compared with present requirements, but only a fraction of the pertinent ores is sufficiently rich for commercial exploitation. Of the total of 3x1011 tonnes of PGMs in the earth’s crust, 3x103 tonnes have been mined, and 7x1010 tonnes are minable (Renner and Schmuckler, 1991). The total worldwide supply of Pt for 1999 and 2000 was 138 tonnes and 153 tonnes respectively for Pd 230 tonnes and 224 tonnes respectively, and for Rh 14.2 tonnes and 20.9 tonnes respectively (Johnson Matthey, 2000) Uses of platinum group metals. By far the greatest use of PGMs both in Europe and worldwide is in vehicle catalysts, with additional major uses in the chemical industry, electrical and electronics industries, petroleum industry, the manufacture of jewellery, as a cancer treating drug in medicine, as alloys in dentistry and in the glass industry. Demands by application for 1999 and 2000 for PGMs are shown in Table a.1. (Johnson Matthey, 2000) 114 Section 6. Case Studies TABLE a.1 Platinum Group Metals Demand by Application (Worldwide) Application kg 1999 (kg) 2000 (kg) PLATINUM Autocatalysts: gross 45600 51000 Autocatalysts: recovery -12000 -13000 Jewellery 79400 83300 Industrial 38400 41400 Investment 5100 -1420 Total Demand (Pt) 159000 146000 PALLADIUM Autocatalysts: gross 166700 146000 Autocatalysts: recovery -5530 -6520 Dental 31500 24700 Electronics 56100 58600 Other 16600 15000 Total Demand (Pd) 265000 238000 RHODIUM Autocatalysts: gross 14400 16000 Autocatalysts: recovery -1870 -2240 Chemical 964 992 Electronics 170 170 Glass 851 1050 Other 312 312 Total Demand (Rh) 14900 16200 RUTHENIUM Chemical 2440 1930 Electrochemical 2040 2270 Electronics 5560 6580 Other 1160 1360 Total Demand (Ru) 11200 12100 IRIDIUM Automotive 964 397 Chemical 198 170 Electrochemical 794 680 Other 936 1450 Total Demand (Ir) 2890 2690 115 Section 6. Case Studies Trends over time in platinum and palladium uses by application for Europe are shown in Table a.2 and a.3. TABLE a.2 Platinum demand by application in Europe (kg) Platinum demand 1992 (kg) 1994 (kg) 1996 (kg) 1998 (kg) 2000 (kg) Autocatalyst: gross 16300 17200 14600 15500 17900 Autocatalyst:recovery -142 -284 -567 -851 -1130 Chemical 1420 1420 1700 1700 2410 Electrical 851 709 709 1280 2270 Glass 425 851 1130 709 709 Investment:small 992 1276 142 142 0 Jewellery 2410 2840 3540 4540 5670 Petroleum 567 709 425 425 284 Other 1560 1840 2130 2410 2840 Totals (Pt) 24400 26500 23800 25800 30900 TABLE a.3 Palladium demand by application in Europe (kg) Palladium demand 1992 (kg) 1994 (kg) 1996 (kg) 1998 (kg) 2000 (kg) Autocatalyst: gross 1130 7370 24400 38800 51600 Autocatalyst:recovery 0 0 142 -142 -425 Chemical 2100 1700 1840 1840 2690 Dental 8500 7230 7230 5950 3120 Electronics 5950 7230 8500 7660 7370 Jewellery 992 851 851 1420 1280 Other 425 709 567 709 567 Totals (Pd) 19100 25100 43200 56300 66200 Of particular interest is the increased demand for palladium in Europe, largely in response to the introduction of Euro Stage III legislation from January 2000; palladium – rich catalysts will meet stricter emission limits for petrol models, resulting in a further move away from platinum technology (Johnson Matthey 2000). Catalytic convertors A catalytic converter is a unit about the size of a small silencer that fits into the exhaust system of a car. The metal catalyst is supported on a ceramic honeycomb monolith and housed in a stainless steel box similar in shape to that of a conventional silencer. About 1-3g of PGM is contained in some vehicle exhaust catalysts, approximately 50g of PGM per cubic foot of catalyst (Steger, 1994). Due to the commercial sensitivity of these products it is difficult to obtain data on the exact amounts in each of the many different formulations of catalyst. The honeycomb made of cordierite contains 300 to 400 square channels per square inch (6.45cm2), and is coated with an activated high surface area alumina layer called the washcoat (Farruato, 1992) containing small amounts of the precious metals, platinum, palladium and rhodium in varying proportions. The conventional three-way catalysts typically contain 0.08% platinum, 0.04% palladium and 0.005-007% rhodium (Hoffman, 1989). These metals convert over 90 percent of carbon monoxide (CO), hydrocarbons (HC) and nitrous oxides (NOx) into carbon dioxide (CO2), water (H 2 O) and nitrogen (N2). Platinum is an effective oxidation catalyst for carbon monoxide and hydrocarbons, but it is more sensitive to poisoning than palladium and so can only be used in cars which use unleaded petrol. Palladium is becoming increasingly used instead of platinum due to the higher costs of the latter. The rhodium oxidises the hydrocarbons and reduces the NOx emissions. Base 116 Section 6. Case Studies metals are also incorporated, cerium being the most frequently used; others include calcium, strontium, barium and iron. Chemical fingerprinting of ground autocatalyst materials has been undertaken by laser ablation and analysis by ICP-MS for 31 elements (Rauch et al, 2000). Variations in composition were found to occur in agreement with the known fact that variations occur from one manufacturer to another and from one year to another. An association between PGMs and Ce in road sediments was ascribed to the emission of PGMs as abraded washcoat particles onto which PGMs are bound and of which Ce is a major component. Recycling Of the total platinum consumption in the United States, approximately thirty per cent is accounted for by vehicle catalysts (IPCS, 1991). The recovery of spent autocatalysts from vehicles at the end of their lives is regarded as important and substantial secondary sources of platinum as well as palladium and rhodium (Torma and Gundiler, 1989). The quantity of spent autocatalysts greatly increased in the United States from 1984 to 1988. These scrapped autocatalysts present an important secondary source of the platinum group metals. On current projections it is expected that 3.5 million catalysts will be available for recycling in the UK by 2000. Platinum group metals in the environment. The average concentration of platinum group metals in the lithosphere is estimated to be in the region of 0.001-0.005 mg.kg-1 for Pt, 0.015 mg.kg-1 for Pd, 0.0001 mg.kg-1 for Rh, 0.0001 mg.kg-1 for Ru, 0.005 mg.kg-1 for Os and 0.001 mg.kg-1 for Ir (Greenwood and Earnshaw, 1984). Although a rapid increase in Pd in sediments from the Palace Moat, Tokyo, Japan was reported by Lee (1983) between 1948 and 1973, it seems unlikely that this was connected with car catalytic convertors since there were few in use in Tokyo by 1973. Concentrations of Pt and Pd in Boston Harbour have been investigated to evaluate Pt and Pd accumulation and behaviour in urban coastal sediments (Tuit et al, 2000). Increased levels of both metal of approximately 5 times above background concentrations were ascribed to anthropogenic activity with catalytic convertors a major source. It was concluded that anthropogenic enrichments can significantly influence coastal marine inventories of PGMs.
Load more

Recommended publications
  • Yangonin Blocks Tumor Necrosis Factor-Α–Induced Nuclear Factor-Κb–Dependent Transcription by Inhibiting the Transactivation Potential of the Rela/P65 Subunit
    J Pharmacol Sci 118, 447 – 454 (2012) Journal of Pharmacological Sciences © The Japanese Pharmacological Society Full Paper Yangonin Blocks Tumor Necrosis Factor-α–Induced Nuclear Factor-κB–Dependent Transcription by Inhibiting the Transactivation Potential of the RelA/p65 Subunit Juan Ma1,†, He Liang1,†, Hong Ri Jin2, Nguyen Tien Dat3, Shan Yu Zhang1, Ying Zi Jiang1, Ji Xing Nan1, Donghao Li1, Xue Wu1, Jung Joon Lee1,2,*a, and Xuejun Jin1,*b 1Key Laboratory of Natural Resources of Changbai Mountain & Functional Molecules, Yanbian University, Ministry of Education, Yanji Jilin 133002, China 2Center for Molecular Cancer Research, Korea Research Institute of Bioscience and Biotechnology, Ochang, Chungbuk 363-883, Republic of Korea 3Institute of Marine Biochemistry, Vietnam Academy of Science and Technology, 18-Hoang Quoc Viet, Hanoi, Vietnam Received November 13, 2011; Accepted January 23, 2012 Abstract. The nuclear factor-κB (NF-κB) transcription factors control many physiological pro- cesses including inflammation, immunity, and apoptosis. In our search for NF-κB inhibitors from natural resources, we identified yangonin from Piper methysticum as an inhibitor of NF-κB activa- tion. In the present study, we demonstrate that yangonin potently inhibits NF-κB activation through suppression of the transcriptional activity of the RelA/p65 subunit of NF-κB. This compound sig- nificantly inhibited the induced expression of the NF-κB-reporter gene. However, this compound did not interfere with tumor necrosis factor-α (TNF-α)-induced inhibitor of κBα (IκBα) degrada- tion, p65 nuclear translocation, and DNA-binding activity of NF-κB. Further analysis revealed that yangonin inhibited not only the induced NF-κB activation by overexpression of RelA/p65, but also transactivation activity of RelA/p65.
    [Show full text]
  • Herbal Insomnia Medications That Target Gabaergic Systems: a Review of the Psychopharmacological Evidence
    Send Orders for Reprints to [email protected] Current Neuropharmacology, 2014, 12, 000-000 1 Herbal Insomnia Medications that Target GABAergic Systems: A Review of the Psychopharmacological Evidence Yuan Shia, Jing-Wen Donga, Jiang-He Zhaob, Li-Na Tanga and Jian-Jun Zhanga,* aState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China; bDepartment of Pharmacology, School of Marine, Shandong University, Weihai, P.R. China Abstract: Insomnia is a common sleep disorder which is prevalent in women and the elderly. Current insomnia drugs mainly target the -aminobutyric acid (GABA) receptor, melatonin receptor, histamine receptor, orexin, and serotonin receptor. GABAA receptor modulators are ordinarily used to manage insomnia, but they are known to affect sleep maintenance, including residual effects, tolerance, and dependence. In an effort to discover new drugs that relieve insomnia symptoms while avoiding side effects, numerous studies focusing on the neurotransmitter GABA and herbal medicines have been conducted. Traditional herbal medicines, such as Piper methysticum and the seed of Zizyphus jujuba Mill var. spinosa, have been widely reported to improve sleep and other mental disorders. These herbal medicines have been applied for many years in folk medicine, and extracts of these medicines have been used to study their pharmacological actions and mechanisms. Although effective and relatively safe, natural plant products have some side effects, such as hepatotoxicity and skin reactions effects of Piper methysticum. In addition, there are insufficient evidences to certify the safety of most traditional herbal medicine. In this review, we provide an overview of the current state of knowledge regarding a variety of natural plant products that are commonly used to treat insomnia to facilitate future studies.
    [Show full text]
  • Central Valley Toxicology Drug List
    Chloroform ~F~ Lithium ~A~ Chlorpheniramine Loratadine Famotidine Acebutolol Chlorpromazine Lorazepam Fenoprofen Acetaminophen Cimetidine Loxapine Fentanyl Acetone Citalopram LSD (Lysergide) Fexofenadine 6-mono- Clomipramine acetylmorphine Flecainide ~M~ Clonazepam a-Hydroxyalprazolam Fluconazole Maprotiline Clonidine a-Hydroxytriazolam Flunitrazepam MDA Clorazepate Albuterol Fluoxetine MDMA Clozapine Alprazolam Fluphenazine Medazepam Cocaethylene Amantadine Flurazepam Meperidine Cocaine 7-Aminoflunitrazepam Fluvoxamine Mephobarbital Codeine Amiodarone Fosinopril Meprobamate Conine Amitriptyline Furosemide Mesoridazine Cotinine Amlodipine Methadone Cyanide ~G~ Amobarbital Methanol Cyclobenzaprine Gabapentin Amoxapine d-Methamphetamine Cyclosporine GHB d-Amphetamine l-Methamphetamine Glutethamide l-Amphetamine ~D~ Methapyrilene Guaifenesin Aprobarbital Demoxepam Methaqualone Atenolol Desalkylfurazepam ~H~ Methocarbamol Atropine Desipramine Halazepam Methylphenidate ~B~ Desmethyldoxepin Haloperidol Methyprylon Dextromethoraphan Heroin Metoclopramide Baclofen Diazepam Hexobarbital Metoprolol Barbital Digoxin Hydrocodone Mexiletine Benzoylecgonine Dihydrocodein Hydromorphone Midazolam Benzphetamine Dihydrokevain Hydroxychloroquine Mirtazapine Benztropine Diltiazem Hydroxyzine Morphine (Total/Free) Brodificoum Dimenhydrinate Bromazepam ~N~ Diphenhydramine ~I~ Bupivacaine Nafcillin Disopyramide Ibuprofen Buprenorphine Naloxone Doxapram Imipramine Bupropion Naltrexone Doxazosin Indomethacin Buspirone NAPA Doxepin Isoniazid Butabarbital Naproxen
    [Show full text]
  • Herbal Medicines in Pregnancy and Lactation : an Evidence-Based
    00 Prelims 1410 10/25/05 2:13 PM Page i Herbal Medicines in Pregnancy and Lactation An Evidence-Based Approach Edward Mills DPh MSc (Oxon) Director, Division of Clinical Epidemiology Canadian College of Naturopathic Medicine North York, Ontario, Canada Jean-Jacques Duguoa MSc (cand.) ND Naturopathic Doctor Toronto Western Hospital Assistant Professor Division of Clinical Epidemiology Canadian College of Naturopathic Medicine North York, Ontario, Canada Dan Perri BScPharm MD MSc Clinical Pharmacology Fellow University of Toronto Toronto, Ontario, Canada Gideon Koren MD FACMT FRCP Director of Motherisk Professor of Medicine, Pediatrics and Pharmacology University of Toronto Toronto, Ontario, Canada With a contribution from Paul Richard Saunders PhD ND DHANP 00 Prelims 1410 10/25/05 2:13 PM Page ii © 2006 Taylor & Francis Medical, an imprint of the Taylor & Francis Group First published in the United Kingdom in 2006 by Taylor & Francis Medical, an imprint of the Taylor & Francis Group, 2 Park Square, Milton Park, Abingdon, Oxon OX14 4RN Tel.: ϩ44 (0)20 7017 6000 Fax.: ϩ44 (0)20 7017 6699 E-mail: [email protected] Website: www.tandf.co.uk/medicine All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or trans- mitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publisher or in accordance with the provisions of the Copyright, Designs and Patents Act 1988 or under the terms of any licence permitting limited copying issued by the Copyright Licensing Agency, 90 Tottenham Court Road, London W1P 0LP.
    [Show full text]
  • Plant-Based Medicines for Anxiety Disorders, Part 2: a Review of Clinical Studies with Supporting Preclinical Evidence
    CNS Drugs 2013; 24 (5) Review Article Running Header: Plant-Based Anxiolytic Psychopharmacology Plant-Based Medicines for Anxiety Disorders, Part 2: A Review of Clinical Studies with Supporting Preclinical Evidence Jerome Sarris,1,2 Erica McIntyre3 and David A. Camfield2 1 Department of Psychiatry, Faculty of Medicine, University of Melbourne, Richmond, VIC, Australia 2 The Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne, VIC, Australia 3 School of Psychology, Charles Sturt University, Wagga Wagga, NSW, Australia Correspondence: Jerome Sarris, Department of Psychiatry and The Melbourne Clinic, University of Melbourne, 2 Salisbury Street, Richmond, VIC 3121, Australia. Email: [email protected], Acknowledgements Dr Jerome Sarris is funded by an Australian National Health & Medical Research Council fellowship (NHMRC funding ID 628875), in a strategic partnership with The University of Melbourne, The Centre for Human Psychopharmacology at the Swinburne University of Technology. Jerome Sarris, Erica McIntyre and David A. Camfield have no conflicts of interest that are directly relevant to the content of this article. 1 Abstract Research in the area of herbal psychopharmacology has revealed a variety of promising medicines that may provide benefit in the treatment of general anxiety and specific anxiety disorders. However, a comprehensive review of plant-based anxiolytics has been absent to date. Thus, our aim was to provide a comprehensive narrative review of plant-based medicines that have clinical and/or preclinical evidence of anxiolytic activity. We present the article in two parts. In part one, we reviewed herbal medicines for which only preclinical investigations for anxiolytic activity have been performed. In this current article (part two), we review herbal medicines for which there have been both preclinical and clinical investigations for anxiolytic activity.
    [Show full text]
  • CAS Number Index
    2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5
    [Show full text]
  • Kava - the Unfolding Story: Report on a Work-In-Progress
    Article Kava - the unfolding story: Report on a work-in-progress. Denham, Alison, McIntyre, Michael and Whitehouse, Jule Available at http://clok.uclan.ac.uk/9455/ Denham, Alison, McIntyre, Michael and Whitehouse, Jule Kava - the unfolding story: Report on a work-in-progress. Journal of Alternative and Complementary Medicine, 8 (3). pp. 237-263. It is advisable to refer to the publisher’s version if you intend to cite from the work. For more information about UCLan’s research in this area go to http://www.uclan.ac.uk/researchgroups/ and search for <name of research Group>. For information about Research generally at UCLan please go to http://www.uclan.ac.uk/research/ All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the policies page. CLoK Central Lancashire online Knowledge www.clok.uclan.ac.uk THE JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE Volume 8, Number 3, 2002, pp. 237–263 © Mary Ann Liebert, Inc. SPECIAL REPORT Kava—the Unfolding Story: Report on a Work-in-Progress ALISON DENHAM, B.A. (Soc.), M.N.I.M.H., 1 MICHAEL McINTYRE, M.A., F.N.I.M.H., F.R.C.H.M., M.B.Ac.C., 2 and JULIE WHITEHOUSE, Ph.D., M.N.I.M.H. 3 ABSTRACT This paper, originated as a submission (now updated) to the U.K. Medicines Control Agency and Committee of Safety of Medicines (CSM) on January 11, 2002, in response to a report circu- lated by the German Federal Institute for Drugs and Medical Products (German initials are BfArM), a compilation of which is summarized in Appendix 2.
    [Show full text]
  • Letters to the Editor
    Letters to the Editor Internet Pharmacy Prescription complete the medication database. Of course, patients can abuse and Phentermine Overdose any medications, so collaboration between pharmacies and physicians is essential to minimize this risk. Sir: The Internet is now widely used by patients for both Dr. Takeshita reports no financial or other relationship relevant to the health information and prescription services. Yet, a MEDLINE subject matter of this letter. search in January 2002 using the phrase “Internet pharmacy” showed a total of 99 articles; nearly all were geared toward REFERENCES health care management or the general public. There are only a few published reports of bad outcome resulting from medical 1 1. Crocco AG, Villasis-Keever M, Jadad AR. Analysis of cases of information obtained from the Internet. The U.S. Food and harm associated with use of health information on the Internet. Drug Administration noted 326 Internet sites selling pharma- JAMA 2002;287:2867–2871 ceutical products.2 The exact numbers are difficult to quantify 2. Henney JE. Cyberpharmacies and the role of the US Food and Drug as Web sites are constantly changing. I report a case of overdose Administration. J Med Internet Res 2001;3:E3 with phentermine that was obtained through an Internet 3. Gardin JM, Schumacher D, Constantine G, et al. Valvular abnormali- pharmacy. ties and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000;283:1703–1709 4. Koury E, Stone CK, Stapczynski JS, et al. Sympathetic overactivity Case report. Ms. A, a 20-year-old woman with a prior from fenfluramine-phentermine overdose.
    [Show full text]
  • Please Check Desired Specimen Type & Drugs/Drug Classes for Testing
    PATIENT INFORMATION PRACTICE INFORMATION ____________________________________ _____________________________________ _______ ________________________ __________________ Last Name First Name MI Facility/Group Referring Physician ________/________/________ Social Security: _________-_________-________ ☐ Male ☐ Female ___________________________________________ Date of Birth Address NPI Provider Nr. __________________________________________________________________ Address DIAGNOSTIC CODES (ICD-10 codes): _____________________________ ☐ Self-Pay (attach Information) ☐ Commercial Insurance (attach copy) ☐ W/C (Date of Injury): ____________ ☐ Medicare (attach copy of Insurance) I certify that I have voluntarily provided a fresh unadulterated urine/dried blood/oral fluid specimen for analytical testing. The information provided on this form and on the label affixed to the specimen is accurate. I authorize lab to release the results of this testing to the ordering physician. I also authorize lab to bill my insurance provider and to receive payment of benefits for the tests ordered by my physician. I further authorize lab and the ordering physician to release to my insurance provider any medical information necessary to process this claim. I acknowledge that lab may be an out-of-network facility with my insurance provider. Patient Signature (or Legal Guardian): ___________________________________________________________________________ Date: _______________ TEST PANELS (please check desired specimen type & drugs/drug classes for testing): ☐ URINE
    [Show full text]
  • Kava Kava Extract Is Available from Ashland Chemical Co., Mini Star International, Inc., and QBI (Quality Botanical Ingredients, Inc.)
    SUMMARY OF DATA FOR CHEMICAL SELECTION Kava Kava 9000-38-8; 84696-40-2 November 1998 TABLE OF CONTENTS Basis for Nomination Chemical Identification Production Information Use Pattern Human Exposure Regulatory Status Evidence for Possible Carcinogenic Activity Human Data Animal Data Metabolism Other Biological Effects Structure-Activity Relationships References BASIS OF NOMINATION TO THE CSWG Kava kava is brought to the attention of the CSWG because it is a rapidly growing, highly used dietary supplement introduced into the mainstream U.S. market relatively recently. Through this use, millions of consumers using antianxiety preparations are potentially exposed to kava kava. A traditional beverage of various Pacific Basin countries, kava clearly has psychoactive properties. The effects of its long-term consumption have not been documented adequately; preliminary studies suggest possibly serious organ system effects. The potential carcinogenicity of kava and its principal constituents are unknown. INPUT FROM GOVERNMENT AGENCIES/INDUSTRY The U.S. Pharmacopeia is in the process of reviewing kava kava. No decision on preparation of a monograph has been made. SELECTION STATUS ACTION BY CSWG: 12/14/98 Studies requested: - Toxicological evaluation, to include studies of reproductive toxicity and neurotoxicity - Genotoxicity Priority: High Rationale/Remarks: - Significant human exposure - Leading dietary supplement with rapidly growing use - Concern that kava has been promoted as a substitute for ritilin in children - Test extract standardized to 30 percent kavalactones - NCI is conducting studies in Salmonella typhimurium CHEMICAL IDENTIFICATION CAS Registry Number: 9000-38-8 Kava-kava resin (8CI) Chemical Abstract Service Name: 84696-40-2 CAS Registry Number: Pepper (Piper), P. methysticum, ext. Chemical Abstract Service Name: Extract of kava; kava extract; Piper Synonyms and Trade Names: methisticum extract Description: The tropical shrub Piper methysticum is widely cultivated in the South Pacific.
    [Show full text]
  • Kavain, the Major Constituent of the Anxiolytic Kava
    RESEARCH ARTICLE Kavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism Han Chow Chua1, Emilie T. H. Christensen1,2, Kirsten Hoestgaard-Jensen2, Leonny Y. Hartiadi1, Iqbal Ramzan1, Anders A. Jensen2, Nathan L. Absalom1, Mary Chebib1* 1 Faculty of Pharmacy, The University of Sydney, Sydney, New South Wales, Australia, 2 Department of a11111 Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark * [email protected] Abstract OPEN ACCESS Extracts of the pepper plant kava (Piper methysticum) are effective in alleviating anxiety in Citation: Chua HC, Christensen ETH, Hoestgaard- Jensen K, Hartiadi LY, Ramzan I, Jensen AA, et al. clinical trials. Despite the long-standing therapeutic interest in kava, the molecular target(s) (2016) Kavain, the Major Constituent of the Anxiolytic of the pharmacologically active constituents, kavalactones have not been established. γ- Kava Extract, Potentiates GABAA Receptors: Aminobutyric acid type A receptors (GABAARs) are assumed to be the in vivo molecular tar- Functional Characteristics and Molecular Mechanism. PLoS ONE 11(6): e0157700. doi:10.1371/journal. get of kavalactones based on data from binding assays, but evidence in support of a direct pone.0157700 interaction between kavalactones and GABAARs is scarce and equivocal. In this study, we Editor: Steven Barnes, Dalhousie University, characterised the functional properties of the major anxiolytic kavalactone, kavain at human CANADA recombinant α1β2, β2γ2L, αxβ2γ2L (x = 1, 2, 3 and 5), α1βxγ2L (x = 1, 2 and 3) and α4β2δ Received: March 24, 2016 GABAARs expressed in Xenopus oocytes using the two-electrode voltage clamp technique.
    [Show full text]
  • Analytical Studies on the Kavain Metabolism in Human Specimen and Liver Cell Lines
    Analytical studies on the kavain metabolism in human specimen and liver cell lines Inaugural-Dissertation zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultät der Heinrich-Heine-Universität Düsseldorf Vorgelegt von Fuad Ali Tarbah aus Derna, Libyen Düsseldorf 2003 Gedruckt mit Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der Heinrich-Heine-Universität Düsseldorf Referent: Prof. Dr. Th. Daldrup Korreferent: Prof. Dr. G. Willuhn, Prof. Dr. H. Weber Tag der mündlichen Prüfung: 17. 12. 2003 Parts of this Ph.D. Thesis have already been presented and/or published in: Tarbah F. A., Mahler H., Temme O. and Daldrup Th. Mass spectral characterisation of hepatic cell metabolites of D,L-kavain using HPLC and GC/MS systems. Special issue: 37th TIAFT triennial meeting “Problems of Forensic Sciences” XLII: 173-180 (1999) Tarbah F. A., Mahler H., Temme O. and Daldrup Th. Determination of D,L-kavain and its metabolites in blood, serum and urine. Rapid quantitative method using fluid/fluid extraction and gas chromatography/mass spectrometry (GC/MS). Poster in 79. Jahrestagung der Deutschen Gesellschaft für Rechtsmedizin, Medizinische Einrichtungen der Universität / Gesamthochschule Essen (2000) Tarbah F., Mahler H., Kardel B., Weinmann W., Hafner D. and Daldrup Th. Kinetics of kavain and its metabolites after oral application. J. Chromatogr. B 789 (1): 115-130 (2003) Cabalion P., Barguil Y., Duhet D., Mandeau A., Warter S., Russmann S., Tarbah F. and Daldrup Th. Kava in modern therapeutic uses: to a better evaluation
    [Show full text]